KY-1044 (Alomfilimab, SAR 445256) is a fully human IgG1 antibody targeting inducible costimulatory receptor (ICOS). KY-1044 depletes ICOShigh cells via antibody-dependent cellular cytotoxicity (ADCC) through the engagement of FcgRIIIa. KY-1044 act as a costimulatory molecule on cells expressing lower ICOS levels, such as CD8+ TEff cells (through FcgR-dependent clustering). KY-1044 exploit the differential expression of ICOS on T-cell subtypes to improve the intratumoral immune contexture and restore an antitumor immune response[1].
Molecular Weight:
(146.5 kDa)
Purity:
99.51
CAS Number:
[2489390-15-8]
Target:
CD28
Application Notes:
MCE Product type: Inhibitory Antibodies
* VAT and and shipping costs not included. Errors and price changes excepted
